Lung cancer drug resistance explained by computer simulation

Computer simulations of epidermal growth factor receptor (EGFR) with lung cancer drug osimertinib have explained why a mutation in the protein (L718Q) renders the drug inactive. This work was carried out as a collaboration between the Mulholland group, The Drug Design and Discovery group of the Department of Food and Drug at the University of Parma and the Medical Oncology Unit, University Hospital of Parma.

For more information see:

http://www.bris.ac.uk/news/2018/february/lung-cancer-drug-resistance.html